Single arm, open label, signal seeking, phase IIa trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations

Trial Profile

Single arm, open label, signal seeking, phase IIa trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2018 New trial record
    • 22 Feb 2018 According to an Australian New Zealand Clinical Trials Registry record, the anticipated date of last participant enrolment is 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top